Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
2 days ago
Among patients with moderate-to-severe psoriasis, the use of biologics appears to lower the risk of being hospitalized for the novel coronavirus disease (COVID-19), a new study has found.

Omalizumab shows sustained benefits in chronic rhinosinusitis with polyps

Pearl Toh
10 Dec 2020

The benefits of omalizumab in symptom improvements continue to hold up over 52 weeks in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), according to data from the extension phase of POLYP1 and POLYP2 studies presented at the ACAAI 2020 Meeting.

Long-term treatment of CRSwNP presents a significant unmet need, said presenting author Dr Philippe Gevaert of Ghent University in Ghent, Belgium.

Nasal polyps can lead to nasal congestion and a loss of smell. Often, it also co-occurs with other respiratory conditions, for instance, allergies and asthma.

“With omalizumab, we observed significantly reduced nasal polyps and congestion symptoms in adults who had nasal polyps in two pivotal phase III studies,” said study co-investigator Dr Joseph Han from Eastern Virginia Medical School in Norfolk, Virginia, US.

“Omalizumab provides a new option for treating these patients, who often have other respiratory and allergic conditions that may further worsen symptoms,” he added.

Omalizumab is a humanized monoclonal antibody which binds to local circulating immunoglobulin E (IgE) to reduce inflammation in nasal polyps.

The current phase III, open-label extension study enrolled 249 adult patients who had completed the double-blind phase which previously randomized them in a 1:1 ratio to receive either omalizumab or placebo for 24 weeks. Participants were CRSwNP patients with inadequate response to intranasal corticosteroids. [ACAAI 2020, abstract D202] 

All patients were treated with omalizumab in the open-label extension phase for another 28 weeks, followed by treatment withdrawal and a further 24 weeks of follow-up.

Among patients previously randomized to omalizumab and continued on treatment in the open-label phase, improvements persisted through 52 weeks across multiple efficacy endpoints, including nasal congestion scores (mean change, -0.99, 95 percent confidence interval [CI], -1.14 to -0.83) and nasal polyp scores (mean change -0.97, 95 CI, -1.25 to -0.69).

Similarly, patient-reported outcome measure using the Sino-Nasal Outcome Test (SNOT) also showed significant improvement over 52 weeks (mean change, -22.39, 95 percent CI, -25.39 to -19.40).

Those previously randomized to the placebo arm in the double-blind phase also saw substantial and rapid improvements with omalizumab at week 52 in the extension study.

“Scores gradually worsened following omalizumab withdrawal, but remained below pretreatment levels [ie, better] at week 76,” said Gevaert.

Safety profile was similar to those previously observed in the double-blind phase, with a generally well tolerated profile. Nasopharyngitis was the most common adverse event reported during treatment, occurring at a rate of 4.8 percent, reported Gevaert.

“The safety and efficacy profile from this study supports continued omalizumab treatment for patients with CRSwNP,” he concluded.

Based on data from POLYP1 and POLYP2, omalizumab has just recently been approved as add-on maintenance therapy for nasal polyps in adults with inadequate response to intranasal corticosteroids. Omalizumab was previously approved for treatment of moderate-to-severe persistent allergic asthma.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
2 days ago
Among patients with moderate-to-severe psoriasis, the use of biologics appears to lower the risk of being hospitalized for the novel coronavirus disease (COVID-19), a new study has found.